Invivyd, Inc.
VBY329
RSV
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for VBY329 in RSV are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Goal is for first- and best-in-class mAb for • Advancement toward IND-readiness 2H 2026 treatment, prophylaxis, and pediatric vaccine schedule enhancement”